- Home
- PSF vs ACIU Comparison
PSF vs ACIU Comparison
Compare PSF & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- ACIU
- Stock Information
- Founded
- PSF 2010
- ACIU 2003
- Country
- PSF United States
- ACIU Switzerland
- Employees
- PSF N/A
- ACIU N/A
- Industry
- PSF Investment Managers
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- PSF Finance
- ACIU Health Care
- Exchange
- PSF Nasdaq
- ACIU Nasdaq
- Market Cap
- PSF 245.5M
- ACIU 213.3M
- IPO Year
- PSF N/A
- ACIU 2016
- Fundamental
- Price
- PSF $20.61
- ACIU $2.43
- Analyst Decision
- PSF
- ACIU Strong Buy
- Analyst Count
- PSF 0
- ACIU 2
- Target Price
- PSF N/A
- ACIU $10.00
- AVG Volume (30 Days)
- PSF 25.0K
- ACIU 125.7K
- Earning Date
- PSF 01-01-0001
- ACIU 11-04-2025
- Dividend Yield
- PSF 7.69%
- ACIU N/A
- EPS Growth
- PSF N/A
- ACIU N/A
- EPS
- PSF N/A
- ACIU N/A
- Revenue
- PSF N/A
- ACIU $36,362,036.00
- Revenue This Year
- PSF N/A
- ACIU N/A
- Revenue Next Year
- PSF N/A
- ACIU $1,022.98
- P/E Ratio
- PSF N/A
- ACIU N/A
- Revenue Growth
- PSF N/A
- ACIU 86.71
- 52 Week Low
- PSF $16.00
- ACIU $1.43
- 52 Week High
- PSF $20.19
- ACIU $3.98
- Technical
- Relative Strength Index (RSI)
- PSF 60.87
- ACIU 62.18
- Support Level
- PSF $20.32
- ACIU $2.12
- Resistance Level
- PSF $20.60
- ACIU $2.35
- Average True Range (ATR)
- PSF 0.14
- ACIU 0.13
- MACD
- PSF 0.01
- ACIU 0.03
- Stochastic Oscillator
- PSF 100.00
- ACIU 97.56
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.